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Objectives This study sought to assess whether an antisense oligonucleotide (ASO) directed to apolipoprotein (a) [apo(a)]
reduces apo(a) and lipoprotein (a) [Lp(a)] levels in transgenic mouse models.
Background Elevated Lp(a) is a causal, independent, genetic risk factor for cardiovascular disease and myocardial infarction.
Effective therapies to specifically lower plasma Lp(a) levels are lacking.
Methods Three transgenic mouse models were utilized: 8K-apo(a) mice expressing 8 kringle IV (KIV) repeats with a single
copy of KIV-2; 8K-Lp(a) mice expressing both the 8K apo(a) plus human apolipoprotein B-100; and 12K-apo(a)
mice expressing a 12K apo(a) with 3 KIV-2 repeats. The mice were treated intraperitoneally with saline, a control
ASO, or ASO 144367 directed to KIV-2 for 4 to 6 weeks. Apo(a), Lp(a), and oxidized phospholipids present on
human apoB (OxPL/h-apoB) or apo(a) [OxPL/apo(a)] were measured at baseline and on and off therapy.
Results ASO 144367 significantly reduced Lp(a) by 24.8% in 8K-Lp(a) mice, and reduced apo(a) levels by 19.2% in 8K-
Lp(a) mice, 30.0% in 8K-apo(a) mice, and 86% in 12K-apo(a) mice; ASO 144367 also significantly reduced
OxPL/apoB 22.4% in 8K-Lp(a) mice, and OxPL/apo(a) levels by 19.9% in 8K-Lp(a) mice, 22.1% in 8K-apo(a)
mice, and 92.5% in 12K-apo(a) mice (p  0.004, or less, for all). No significant changes occurred in Lp(a),
apo(a), OxPL/apoB, or OxPL/apo(a) levels with control ASO or saline.
Conclusions This study documents the first specific therapy, to our knowledge, for lowering apo(a)/Lp(a) levels and their as-
sociated OxPL. A more potent effect was documented in mice expressing apo(a) with multiple KIV-2 repeats.
Targeting liver expression of apo(a) with ASOs directed to KIV-2 repeats may provide an effective approach to
lower elevated Lp(a) levels in humans. (J Am Coll Cardiol 2011;57:1611–21) © 2011 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.052Lipoprotein (a) [Lp(a)] represents a unique class of lipo-
proteins that are composed of apolipoprotein (a) [apo(a)]
covalently bound to apolipoprotein B-100 (apoB) by a
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2010, accepted October 18, 2010.disulfide bond (1). Apo(a) expression leading to Lp(a)
formation is restricted to humans, apes, and Old World
monkeys and an unrelated version in European hedgehogs
(2). Elevated Lp(a) levels (25 to 30 mg/dl) are present in
up to 30% of whites and 70% of blacks (3). Despite having
been discovered nearly 50 years ago, a physiological function
for Lp(a) has not been identified. Plasma Lp(a) concentra-
tions are primarily determined by the LPA gene locus and
are only minimally affected by environmental factors (4).
The LPA gene encodes for repeating apo(a) subunits called
kringles (K), and includes 10 unique copies of KIV, which
additionally includes variable numbers of identical KIV-2
repeats (from 3 to40), KV, and a protease-like domain that
is catalytically inactive. Most subjects have 2 distinct apo(a)
alleles, which vary in size due to kringle copy number, resulting
in a marked size heterogeneity of the expressed apo(a) protein.
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ASO Reduces Apo(a)/Lp(a) OxPL/ApoB Levels April 12, 2011:1611–21Lp(a) levels are generally inversely
associated with apo(a) size, and the
variation in kringle number results
in a 1,000-fold (0.1 to 250
mg/dl) range of plasma Lp(a) lev-
els among individuals, unlike most
proteins where normal levels may
vary by 3- to 5-fold.
Lp(a) has proatherogenic prop-
erties due to its low-density lipo-
protein (LDL) component, but
the apo(a) moiety may confer ad-
ditional proinflammatory and
proatherogenic properties (1).
In addition, Lp(a) may be pro-
hrombotic by inhibiting fibrinolysis because of its high
omology to plasminogen and its enhancement of plate-
et aggregation (5). After a large series of studies, our
roup has proposed the hypothesis that some of the
therogenic properties of Lp(a) may be mediated by its
nique ability among lipoproteins to bind proinflamma-
ory oxidized phospholipids (OxPL) (6,7). Elevated
p(a) levels in humans are associated with increased risk
f cardiac death, myocardial infarction, stroke, and pe-
ipheral arterial disease, particularly in subjects with small
po(a) isoforms (8 –10). Recently, genetic association
tudies with Mendelian randomization approaches have
learly demonstrated that Lp(a) is a strong, causal,
enetic risk factor in myocardial infarction and coronary
rtery disease (11). In fact, its association with coronary
rtery disease was the strongest in a study evaluating 48,742
ingle nucleotide polymorphisms (SNPs) in 2,100 candidate
enes, including a higher odds ratio than the previously
eported 9p21 SNP (12).
Apo(a) is synthesized primarily in the liver, where it is
ubsequently covalently linked to apoB-100 to form the Lp(a)
ipoprotein. Effective therapeutic modalities to reduce Lp(a)
evels in humans, and particularly drugs that specifically target
nly Lp(a), are lacking. Antisense oligonucleotides (ASO) are
merging as viable therapeutic agents to treat disorders where
verexpression of proteins is associated with a disease process.
n the current study, we hypothesized that an ASO targeted to
po(a) would reduce Lp(a) levels and their accompanying
xPL in apo(a)/Lp(a) transgenic mice.
ethods
ntisense oligonucleotides. ASO 144367 is targeted to
osition 174 within KIV-2 of the apo(a) transcript and is a
-10-5 MOE gapmer, a similar class ASO as mipomersen,
hich is directed to human apolipoprotein B-100 (apoB) (13).
t is composed of 20-nucleotide phosphorothioate oligonucle-
tides with 5 2=-O-(2-methoxyethyl) modified ribonucleosides
2=-MOE) at the 3= and 5= ends with 10 2=-deoxynucleosides
n-between. The sequence of ASO 144367 is 5=-GGCAGG-
Abbreviations
and Acronyms
apo  apolipoprotein
ASO  antisense
oligonucleotide
LDL  low-density
lipoprotein
Lp  lipoprotein
OxPL  oxidized
phospholipids
RLU  relative light units
SNP  single nucleotide
polymorphismCCTTCCTGTGACA-3=. ASO 144367 does not hybrid-ze with plasminogen mRNA. ASO 141923 (5=-CCTTC-
CTGAAGGTTCCTCC-3=), which is the same chemical
lass as ASO 144367 but does not hybridize to apo(a) mRNA
r to murine or human apoB-100, was used as a control.
ransgenic mice. We used 3 unique transgenic mouse
odels overexpressing apo(a), which are defined by the
umber of Kringle (K) IV repeats, to assess the safety and
fficacy of ASO 144367.
8K-APO(A) MICE. This mini apo(a) construct contains the
apoE promoter, 8 KIV repeats (KIV-1, a single copy of KIV-2,
a fusion of KIV-3 and KIV-5, and KIV-6 to KIV-10), KV,
and the protease-like domain. The generation of 8K-apo(a)
mice on a C57BL6/SJL background was previously described
(14,15).
8K-LP(A) MICE. The 8K-Lp(a) mice were generated by cross-
ng hemizygous 8K-apo(a) mice with hemizygous mice over-
xpressing human apoB-100, as previously described (14,15).
12K-APO(A) MICE. The generation of 12K-apo(a) mice on an
FVB background overexpressing a natural 12KIV apo(a) iso-
form was previously described (16). This construct contains a
270-kb yeast artificial chromosome with a human genomic
DNA clone containing the intact LPA gene and a 70-kb
LPA-like gene with extensive 60-kb flanking regions on both
sides. 12K-Lp(a) mice were not available for this study.
All murine protocols used in this study were approved by
the University California, San Diego Institutional Animal
Care and Use Committee (IACUC).
Treatment protocol. EFFECT OF ASO 144367 ON LIVER MRNA
APO(A) EXPRESSION. Liver mRNA apo(a) expression was
evaluated in 8 8K-Lp(a) mice (4 received ASO 144367 and
4 saline), in 7 8K-apo(a) mice (4 received ASO 144367 and
3 saline) with a dose of 25 mg/kg intraperitoneally twice
weekly for 4 weeks and in 9 12K-apo(a) mice (3 received
ASO 144367, 3 received control ASO, and 3 saline) at 50
mg/kg intraperitoneally once weekly for 4 weeks.
EFFECT OF ASO 144367 ON LIVER AND KIDNEY FUNCTION
ESTS AND HISTOLOGY. Laboratory tests including liver and
kidney function tests using commercial assays, and histo-
logic analysis of the liver and kidney with hematoxylin and
eosin were performed on the 12K-apo(a) mice and controls.
EFFECT OF ASO 144367 ON APO(A) AND LP(A) LEVELS AND
OXIDIZED PHOSPHOLIPIDS ON APOB AND APO(A). After es-
tablishing that ASO 144367 reduced liver apo(a) expression
in all 3 transgenic models, a study was initiated to assess its
effect on plasma apo(a) and Lp(a) levels. ASO 144367 was
injected intraperitoneally (25 mg/kg in sterile PBS) twice
weekly for 6 weeks into 8K-apo(a) mice and 8K-Lp(a) mice
(n  21 total, 11 and 10 in each group, respectively).
Similarly, control ASO 141923 was injected into 8K-apo(a)
mice and 8K-Lp(a) mice (n  20 total, 10 in each group).
Treatment was given for 6 weeks, and the mice were
observed off treatment for another 6 weeks. Blood samples
were collected at 0, 3 and 6, 9 and 12 weeks.
1613JACC Vol. 57, No. 15, 2011 Merki et al.
April 12, 2011:1611–21 ASO Reduces Apo(a)/Lp(a) OxPL/ApoB LevelsTo assess whether the efficacy of ASO 144367 was
dependent on the number of KIV repeats or the presence of
a genomic versus a cDNA construct, we also performed a
similar study in the 12K-apo(a) mice by injecting them
intraperitoneally (50 mg/kg per week in sterile PBS) on
weeks 0 to 3 and obtaining blood samples at weeks 0, 2, and
4. This dosing strategy was given for convenience as there
are no pharmacokinetic or pharmacodynamic differences
after 2 weeks of dosing with this regimen compared with 25
mg/kg twice weekly (data not shown).
RNA and reverse transcription PCR analysis. Total
RNA was extracted from whole liver tissue and primary
hepatocytes (Qiagen RNeasy, Valencia, California) as pre-
viously described (17). The apo(a) primers used were
5=-CCACAGTGGCCCCGGT-3= and 5=-ACAGGG-
CTTTTCTCAGGTGGT-3= with the fluorescent probe
5=-CCAAGCACAGAGGCTCCTTCTGAACAAG-3=.
The mouse apoB-100 primers were: 5=-CGTGGGCTC-
CAGCATTCTA-3= and 5=-AGTCATTTCTGCCTT-
TGCGTC-3= with fluorescent probe 5=-CCAATGGT-
CGGGCACTGCTCAA-3=. Expression values were
normalized to cyclophilin A. DNA was isolated using
Qiagen DNeasy tissue kit.
Determination of total cholesterol, triglycerides, Lp(a),
and apo(a) levels. Total cholesterol and triglycerides were
determined by commercial enzymatic assays using the
Roche Cobas Mira Plus Analyzer (Roche, Indianapolis,
Indiana). Plasma Lp(a) levels were measured by a sandwich
ELISA, as previously described (15). A detailed description
of the methodology is included in the Online Appendix.
Determination of OxPL on human apoB-100, on apo(a),
and mouse apoB, and determination of apo(a) on mouse
apoB. Chemiluminescence ELISA was used to measure
the amount of OxPL present on various lipoproteins, as
previously described (15). A detailed description of the
methodology is included in the Online Appendix.
Statistical analysis. Differences between the groups were
assessed by Student t test. Analysis of quantitative param-
eters within groups of mice over the time course of the
studies was performed with repeated measures analysis of
variance (ANOVA). Parametric versus nonparametric tests
were performed depending on whether the data were normally
distributed or not normally distributed, respectively. Post-test
analysis was performed for changes within individual time
points with the Bonferroni or Dunn multiple comparison test.
Data represent means  SD in the text and as mean  SEM
in graphs. p  0.05 was considered significant. Statistical
analysis was performed with GraphPad InStat, version 3.02
(GraphPad Software, La Jolla, California).
Results
Baseline lipid and OxPL profiles of the 8K-apo(a) and
8K-Lp(a) transgenic mice. The lipid profiles of these
transgenic mouse lines were previously described (14,15). In
the current study, the cholesterol, triglyceride, Lp(a), apo(a)
levels, and OxPL on human apoB (h-apoB) and mouse
apoB and on apo(a), as well as apo(a) on mouse apoB, are
shown in Table 1. It was noted that 8K-Lp(a) mice have
higher total cholesterol and triglyceride levels than 8K-
apo(a) mice, as previously described (14,15). The median
(range) of Lp(a) levels in the 8K-Lp(a) mice chosen for this
study was 35.5 mg/dl (5.1 to 111 mg/dl). There were no
differences in apo(a) levels between the groups. The OxPL/
h-apoB levels were in the lower range of what we described
recently (15), as this group of mice had lower overall Lp(a)
levels. OxPL/apo(a) levels were similar between groups, but
there was more apo(a) and OxPL associated with the murine
apoB in the 8K-apo(a) mice than in the 8K-Lp(a) mice,
consistent with the fact that apo(a) binds noncovalently to
mouse apoB (14,15). The lipid profiles of the 12K-apo(a) mice
were previously described (18).
The effect of ASO 144367 on liver mRNA apo(a) expression.
The effect of ASO 144367 on hepatic apo(a) mRNA
expression in the 8K-Lp(a) mice and 8K-apo(a) mice was
found to be similar, and therefore, the data were combined.
Compared to saline-injected controls, ASO 144367 reduced
hepatic apo(a) mRNA expression by 52% (p  0.018) (Fig.
1A). In the 12K-apo(a) mice, there was a more potent effect
with a 87% reduction (p  0.012) compared with saline
(Fig. 1B). The control ASO had no effect on apo(a) mRNA
expression. There was no effect of ASO 144367 on hepatic
mouse apoB mRNA expression or mouse plasma apoB
levels (data not shown).
Safety parameters. There were no differences in body weight
or weights of the liver, kidney, and spleen in the 12K-apo(a)
mice treated with saline, ASO control, and ASO 144367 (data
not shown). The Online Appendix describes laboratory pa-
rameters (Online Table 1) and histological analysis (Online
Figure 1) of the liver and kidney, showing no signs of liver or
kidney toxicity.
The effect of ASO 144367 on plasma apo(a) and Lp(a)
levels in 8K-Lp(a) mice and 8K-apo(a) mice. Table 2
displays the changes in total cholesterol, triglycerides, Lp(a),
Baseline Levels of Lipid and Oxidation VariablesTable 1 Baseline Levels of Lipid and Oxidation Variables
8K-apo(a) Mice
(n  21)
8K-Lp(a) Mice
(n  20) p Value
Total cholesterol, mg/dl 124.3 27.2 179.2 25.6 0.001
Triglycerides, mg/dl 101.9 45.2 146.4 33.9 0.001
Lp(a), mg/dl N/A 43.2 33.1 N/A
Lp(a), mg/dl N/A 35.5 (5.1–111.0) N/A
Apo(a), mg/dl 303 229 260 250 0.70
Apo(a), mg/dl 178 (38–753) 186 (36–1080) 0.70
OxPL/h-apoB, RLU N/A 82,209 49,370 N/A
OxPL/m-apoB, RLU 21,257 14,224 10,893 15,573 0.001
OxPL/apo(a), RLU 75,555 38,622 66,399 40,452 0.41
Apo(a)/m-apoB, RLU 4,620 2,723 1,273 2,985 0.001
Apo(a)/m-apoB, ratio 1.72 0.99 0.40 0.86 0.001
Values are mean  SD or median (range).
8K 8 kringle IV repeats; apo(a) apolipoprotein (a); h-apoB human apolipoprotein B; Lp(a)
lipoprotein (a); m-apoB  mouse apolipoprotein B; N/A  not applicable; OxPL  oxidized
phospholipids; RLU  relative light units.
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ASO Reduces Apo(a)/Lp(a) OxPL/ApoB Levels April 12, 2011:1611–21and apo(a) levels in 8K-Lp(a) mice and 8K-apo(a) mice in
response to ASO 144367 or ASO control. Over the 6-week
treatment period, total cholesterol levels were reduced mod-
estly in both 8K-Lp(a) mice and 8K-apo(a) mice treated with
ASO 144367, but not with ASO control. Small, but statisti-
cally significant reductions in total cholesterol were also noted
in 8K-apo(a) mice treated with ASO control.
In 8K-Lp(a) mice, significant reductions in response to
ASO 144367 were noted in both Lp(a) (p  0.001 by
ANOVA) and apo(a) levels (p  0.027 by ANOVA) at 3
and 6 weeks, which then returned toward normal once
therapy was stopped. In contrast, no significant changes
were noted in response to ASO control. Similarly, in
8K-apo(a) mice, significant reductions were noted in apo(a)
levels (p 0.001 by ANOVA) at 3 and 6 weeks, which then
returned to normal once therapy was stopped. No signifi-
cant changes were noted in response to ASO control.
We also evaluated the data as the mean percentage
change from baseline. By 6 weeks, ASO 144367 lowered
Lp(a) levels by 24.8% (p  0.0001) in 8K-Lp(a) mice
Figure 1 Hepatic apo(a) mRNA Expression in Response to
ASO 144367
Effect of antisense oligonucleotide (ASO) 144367 on hepatic apolipoprotein (a)
[apo(a)] mRNA expression in 8K-apo(a) and 8K lipoprotein (a) [8K-Lp(a)] mice
combined (A) and in 12K-apo(a) mice (B). The data are normalized to cyclophi-
lin A expression, and comparison is made to saline and the control ASO. 8K 
8 kringle IV repeats.(Fig. 2A), and apo(a) levels by 31.7% (p  0.001) in m8K-Lp(a) mice and 30.0% (p  0.001) in 8K-apo(a) mice
(Fig. 2B). Lp(a) and apo(a) levels returned to baseline by
3 to 6 weeks off treatment.
The effect of ASO 144367 on OxPL on h-apoB and
apo(a) particles. In 8K-Lp(a) mice, OxPL/h-apoB levels
(as relative light units [RLU]) were reduced by 16.8% at 3
weeks and 22.4 % at 6 weeks, and then returned to baseline
by 9 to 12 weeks (p  0.002 by ANOVA) (Fig. 3A).
Similarly, OxPL/apo(a) levels (as RLU) decreased 12.1% at
3 weeks and 19.9% at 6 weeks, and then returned to baseline
by 9 to 12 weeks (p  0.001 by ANOVA) (Fig. 3B). No
significant changes were noted with ASO control.
In 8K-apo(a) mice, OxPL/h-apoB levels are not measur-
able as they do not have human apoB. OxPL/apo(a) levels
(as RLU) decreased 22.1% at 3 weeks and 11.8 % at 6
weeks, and then returned to baseline by 9 to 12 weeks (p 
.015 by ANOVA) (Fig. 3B). No significant changes were
oted with ASO control.
he effect of ASO 144367 on apo(a) and OxPL associated
ith mouse apoB in 8K-Lp(a) mice and 8K-apo(a) mice.
s noted in Table 1, the 8K-apo(a) mice have higher
po(a)/m-apoB ratios than the 8K-Lp(a) mice, as a greater
roportion of apo(a) associates with mouse apoB, in con-
rast to the 8K-Lp(a) mice where it preferentially associates
ith human apoB as part of the Lp(a) lipoprotein. We
valuated the mean percentage change in apo(a)/m-apoB
nd OxPL/m-apoB in response to ASO 144367 or control
SO. Figure 4A demonstrates that apo(a)/m-apoB levels
ere significantly reduced in 8K-apo(a) mice and 8K-Lp(a)
ice treated with ASO 144367 but not control ASO. In
arallel with these changes, the OxPL/m-apoB levels also
ere significantly reduced in the 8K-apo(a) mice (Fig. 4B).
he effect of ASO 144367 on apo(a), OxPL/apo(a),
po(a)/m-apoB, and OxPL/m-apoB levels in 12K-apo(a)
ice. Table 3 displays the data on changes in apo(a),
xPL/apo(a), apo(a)/m-apoB, and OxPL/m-apoB levels in
he 12K-apo(a) mice and demonstrates significant and
obust reductions in all parameters in response to ASO
44367, whereas no significant changes were noted with
aline or ASO control. The data were also evaluated as
ean percentage change from baseline (Fig. 5), demonstrat-
ng an 86% reduction in apo(a), 93% reduction in OxPL/
po(a), 82% reduction in apo(a)/m-apoB, and 64% reduc-
ion in OxPL/m-apoB (all statistically significant by
NOVA and with post-test analysis).
iscussion
his is the first study, to our knowledge, to demonstrate a
pecific therapy for lowering apo(a) and Lp(a) levels using
n ASO that prevents synthesis of apolipoprotein (a) by
inding to a region on KIV-2 apo(a) mRNA. The findings
ere consistent across 3 unique apo(a)/Lp(a) transgenic
ouse models expressing apo(a) with a variable number of
IV-2 repeats. More potent reduction in hepatic apo(a)
RNA (87%) and apo(a) plasma levels (86%) was noted in
yceride
1615JACC Vol. 57, No. 15, 2011 Merki et al.
April 12, 2011:1611–21 ASO Reduces Apo(a)/Lp(a) OxPL/ApoB Levelsmice overexpressing a human apo(a) genomic construct with
3 KIV-2 repeats compared with a mini apo(a) cDNA
construct with only 1 KIV-2 repeat. Concomitantly with a
reduction in apo(a) and Lp(a) levels, OxPLs associated with
circulating apo(a)/Lp(a) were reduced in relative proportion
to the lowering of apo(a)/Lp(a), consistent with prior
observations that Lp(a) is a carrier of proinflammatory
OxPLs (6,14,19).
There has been considerable controversy about the po-
tential atherogenicity of Lp(a), which was driven by many
factors, including nonstandardized methodologies for mea-
suring Lp(a) levels, issues of sample storage, and inadequate
study design. However, recent meta-analyses (8) and large
clinical studies (9,11,12), some of which included Mende-
lian randomization approaches that allow analyses of risk
based on genetic differences in lifelong Lp(a) levels, have
Lipoprotein Profiles of 8K-Lp(a) and 8K-apo(A) MFollowing Treatm nt With ASO 144367Table 2 Lipopro ein Profiles of 8K-Lp(a) andFollowing Treatment With ASO 144
8K-Lp(a) Mice TC
ASO 144367
Baseline 186.4 20.3 15
3 weeks 156.2 23.4* 16
6 weeks 144.4 20.7† 17
Off therapy
9 weeks 150.3 19.2† 18
12 weeks 160.2 21.6* 19
p-ANOVA 0.001
ASO control
Baseline 171.9 29.3 13
3 weeks 175.2 22.0 13
6 weeks 172.4 16.7 13
Off therapy
9 weeks 166.9 15.8 17
12 weeks 185.9 38.9 16
p-ANOVA 0.010
8K-apo(a) mice TC
ASO 144367
Baseline 140.4 23.6
3 weeks 122.1 20.2
6 weeks 116.9 19.8*
Off therapy
9 weeks 111.2 16.8†
12 weeks 114.5 16.7*
p-ANOVA 0.001
ASO control
Baseline 109.7 22.0
3 weeks 106.7 18.6
6 weeks 105.4 17.7
Off therapy
9 weeks 97.4 21.1†
12 weeks 98.5 18.0
p-ANOVA 0.01
Values are in mg/dl and represent mean SD. p-ANOVA represents re
variable. *p  0.01, †p  0.001, and ‡p  0.05 compared with base
comparisons).
ASO  antisense oligonucleotide; TC  total cholesterol; TG  triglclearly documented that Lp(a) is a causal, independent,genetic risk factor for myocardial infarction and cardiovas-
cular disease. The future challenge is to demonstrate that
Lp(a) is a modifiable risk factor. To accomplish this, specific
therapeutic agents that selectively lower plasma Lp(a) levels
need to demonstrate clinical benefit.
Apolipoprotein (a) is primarily synthesized in the liver, and
although all of the pathways are not fully delineated, it is
thought to then bind extracellularly in the space of Disse to
newly synthesized apoB-100 to create Lp(a) particles. Several
of the synthetic steps in generation of Lp(a) have been
previously delineated in cell culture (20). It is well appreciated
that small apo(a) isoforms, which are more rapidly synthesized,
are associated with higher Lp(a) particle number in plasma and
therefore higher plasma Lp(a) levels. In contrast, larger apo(a)
isoforms take longer to synthesize in the hepatocyte, and
therefore, their production rates are lower, generally leading to
po(A) Mice
Lp(a) apo(a)
32.9 45.2 38.9 297 327
56.8 34.1 27.7† 201 157
61.6 33.0 27.6* 191 163
100.1 41.3 31.0 263 226
73.5 42.9 32.5 263 229
8 0.001 0.05
31.1‡ 41.2 28.2 226 145
47.2 43.1 28.8 253 161
42.6 42.9 26.5 242 166
56.3† 44.6 30.0 251 184
48.3 44.0 31.3 223 145
01 0.76 0.57
TG apo(a)
101.0 31.5 384 242
119.6 51.6 276 159†
141.6 46.4 272 189*
141.6 100.1 323 374
124.0 53.7 374 224
0.13 0.001
102.7 56.4 230 199
108.7 41.4 266 241
91.5 33.5 260 204
96.4 34.0 225 169
109.3 38.4 163 131
0.59 0.65
measures analysis of variance (ANOVA) for the 5 time points for each
ues within each group with Bonferroni multiple comparisons test (10
s; other abbreviations as in Table 1.ice8K-a
367
TG
9.4
7.1
9.3
3.9
0.2
0.2
3.3
9.2
8.0
7.1
1.6
0.0
peated
line vallower plasma levels. In patients with elevated triglyceride levels,
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density lipoprotein particles. Humans generally have no free
apo(a) circulating in plasma, as plasma apoB-100 synthesis is in
excess of synthesis of apo(a).
The clearance of Lp(a) is not well understood, although it
does not appear to involve the LDL receptor and is not
dependent on kringle copy number (20). Murine studies
have suggested the existence of a yet to be identified apo(a)
receptor in the liver (21). In addition, impaired renal
mechanisms may also play a role leading to elevated Lp(a)
levels, but in these patients, there is accumulation of large
but not small apo(a) isoforms. In such patients, a small
proportion of free apo(a) (5% of total) can be found in the
Figure 2 Changes in apo(a) and Lp(a) Levels in Response to A
(A) Mean percentage change in Lp(a) levels in 8K-Lp(a) mice in response to ASO
mice and 8K-apo(a) mice in response to ASO 144367 or ASO control. *p  0.05
tions as in Figure 1.plasma. Furthermore, in some patients in whom Lp(a) isnot measurable in plasma, apo(a) degradation products
generated by proteases and elastases may be found in the
urine, suggesting that there is metabolism of apo(a) that
mediates its clearance. Because Lp(a) is not normally
present in small animal models, it has been difficult to fully
evaluate the syntheses and clearance mechanisms of Lp(a),
and further work in this area is needed to fully understand
all the implications for development of therapeutic agents.
In addition to the size heterogeneity of apo(a) isoforms
influencing plasma Lp(a) levels, it has been recently appre-
ciated that additional genetic differences may play a role
(12,22,23). For example, although it is well known that the
size heterogeneity of the KIV-2 repeats is a direct mediator
44367
7 or ASO control. (B) Mean percentage change in total apo(a) levels in 8K-Lp(a)
p  0.01 for Bonferroni within-group post-test compared to baseline. Abbrevia-SO 1
14436
and **of Lp(a) levels, it explains 50% of the variability. Recent
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April 12, 2011:1611–21 ASO Reduces Apo(a)/Lp(a) OxPL/ApoB Levelsgenetic studies have reported several SNPs that explain an
additional 35% of the variability in plasma Lp(a) levels. In
particular, SNPs rs3798220 and rs10455872 have been
associated with both increased Lp(a) levels and an increased
risk for coronary artery disease (12,22,23). There are also
other SNPs that have been previously identified that can
result in increased Lp(a) levels (4). However, the underlying
mechanisms by which these SNPs mediate elevated Lp(a)
levels are not known, and further research is needed to assess
how they may impact increased synthesis or delayed catab-
Figure 3 Changes in OxPL/h-apoB and OxPL/apo(a) in Respon
(A) Mean percentage change in OxPL/h-apoB levels in 8K-Lp(a) mice in response
8K-Lp(a) mice and 8K-apo(a) mice in response to ASO 144367 or ASO control. *p
H-apoB  human lipoprotein B; OxPL  oxidized phospholipids; other abbreviationolism of Lp(a).This study advances the concept that ASOs directly
targeting apo(a) mRNA synthesis are able to specifically
lower plasma apo(a)/Lp(a) levels. Furthermore, it suggests
that ASOs directed to the multiple identical KIV-2 repeats
are more potent, possibly due to targeting multiple sites on
apo(a) mRNA. Additionally, one may postulate that
genomic apo(a) constructs, which more closely reflect hu-
man apo(a), appear to be optimal substrates for terminating
mechanisms as they require post-transcriptional modifica-
tion in the nucleus to remove noncoding regions. This
ASO 144367
144367 or ASO control. (B) Mean percentage change in OxPL/apo(a) levels in
5 and **p  0.01 for Bonferroni within-group post-test compared to baseline.
Figure 1.se to
to ASO
 0.0
s as inediting requires longer nuclear residence time, which is
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structs do not require this process and are much more
rapidly exported in the cytoplasm, where RNaseH is not
present (24).
This study complements a recent study where we dem-
onstrated significant reductions in Lp(a) levels using mi-
pomersen (15), an ASO directed to human apoB-100 that
is currently being evaluated to lower LDL levels in human
Figure 4 Changes in apo(a)/m-apoB and OxPL/m-apoB in Resp
(A) Mean percentage change in apo(a)/m-apoB levels in 8K-apo(a) mice and 8K-Lp
OxPL/m-apoB levels in 8K-apo(a) mice and 8K-Lp(a) mice in response to ASO 144
test compared to baseline. Abbreviations as in Figures 1 and 3.subjects. In that study (15), mipomersen resulted in a90% reduction in human apoB levels and a correspond-
ing 75% reduction in Lp(a) levels in 8K-Lp(a) mice. This
was mediated by a different mechanism, however, due
exclusively to a marked reduction of human apoB-100
levels without affecting apo(a) mRNA synthesis or
plasma levels.
In the current study, there was a modest reduction in total
cholesterol levels in the mice treated with ASO 144367, but
to ASO 144367
ice in response to ASO 144367 or ASO Control. (B) Mean percentage change in
r ASO control. **p  0.01 and ***p  0.001 for Bonferroni within-group post-onse
(a) m
367 othe mechanism of this lowering is not yet established. We
d
c
m
d
within e
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100 and Lp(a) particles was diminished following treat-
ment with ASO 144367, a similar finding previously
described with mipomersen (15). This is consistent with
the fact that Lp(a) is particularly enriched in OxPL,
which can be bound both covalently to apo(a) and in the
lipid phase of Lp(a), although the relative proportions of
these are not yet fully delineated (6). In agreement with
this, the content of noncovalently bound apo(a) to mouse
apoB, and its OxPL content, was also significantly
reduced with ASO 144367.
Despite the fact that Lp(a) is a carrier of OxPL and
that these 2 parameters correlate highly when measured
in plasma in human populations as a whole, data from the
EPIC (European Prospective Investigation into Cancer
and Nutrition)-Norfolk population demonstrate that
measuring both OxPL/apoB and Lp(a) in patients gives
additive information regarding risk of future coronary
events compared with measuring each alone (25). One
potential explanation for this is derived from the Dallas
Heart Study, where we showed that the correlation
between OxPL/apoB and Lp(a) was strongest when
Lp(a) levels were high in the setting of small apo(a)
isoforms, but the correlation was weak in patients with
low Lp(a) levels and large apo(a) isoforms (7). Because
most patients (80%) have 2 distinct apo(a) isoforms and
since the Lp(a) levels and the OxPL/apoB measures
reflect the net effect of these factors, it is possible the
OxPL/apoB measure may closely reflect the cumulative
atherogenicity of small Lp(a) particles. This was also
demonstrated in the Mayo Clinic study, where we
showed that OxPL/apoB was an independent predictor
of the presence of angiographically defined coronary
artery disease in a multivariable adjusted model that also
Apo(a), OxPL/apo(a), apo(a)/m-apoB, and OxPTable 3 Apo(a), OxPL/apo(a), apo(a)/m-ap
Apo(a)
Apo(a) mice saline
Baseline 91,112 11,506 3
2 weeks 104,911 10,483 4
4 weeks 72,173 21,551 2
p-ANOVA 0.08
Apo(a) mice ASO control
Baseline 74,935 10,318 2
2 weeks 78,473 8,854 3
4 weeks 67,414 42,663 2
p-ANOVA 0.87
Apo(a) mice ASO 144367
Baseline 76,983 14,598 3
2 weeks 17,580 11,162*
4 weeks 11,060 7,137*
p-ANOVA 0.004
Apo(a) values are in RLU and represent mean  SD. p-ANOVA repr
*p 0.01, †p 0.05, and ‡p 0.001 compared with baseline values
Abbreviations as in Tables 1 and 2.contained Lp(a) levels (26). Furthermore, subjects with aSNP rs3798220 have increased plasma levels of OxPL/
apoB, in a setting of elevated Lp(a) levels and small isoforms
(27). These relationships make a plausible pathophysiolog-
ical model in which the oxidized phospholipid content of
Lp(a) appears to be a key component of the atherogenic risk
of Lp(a), along with other potential mechanisms already
described (20). Mechanistic support of these clinical obser-
vations of the atherogenicity of Lp(a) and its associated
OxPL was recently provided by the Tabas laboratory in
collaboration with our group, where it was demonstrated
that Lp(a) and the OxPL that it binds promote apoptosis
in endoplasmic reticulum–stressed macrophages by acti-
vating an ERK-NADPH oxidase– oxidative stress path-
way through a CD36 and toll-like receptor 2 (TLR2)
pathway (28).
Conclusions
We demonstrate the first specific therapy for lowering
apo(a) mRNA expression in the liver and apo(a)/Lp(a)
levels in plasma. These data also suggest that targeting a
kringle repeat sequence may result in optimal apo(a) low-
ering in humans. Assuming that such ASOs are ultimately
approved for clinical investigation, this study demonstrates
in principle that such an approach could be used in patients
to test the hypothesis that lowering plasma Lp(a) levels
reduces cardiovascular events. For example, one could select
patients with increased cardiovascular risk and elevated
Lp(a) levels (i.e., 30 mg/dl [or 75 mmol/l]) and ran-
omize them to ASO therapy versus placebo and evaluate
ardiovascular imaging and clinical endpoints. This study
ay set the stage for future translational research for
eveloping and testing novel therapeutic agents to lower the
poB Levels in 12K-apo(a) Micend OxPL/m-apoB Levels in 12K-apo(a) Mice
/apo(a) apo(a)/m-apoB OxPL/m-apoB
 3,520 61,243 7,436 19,036 1,841
 14,011 89,401 13,915 31,478 13,915
 11,212 65,093 11,584 23,847 7,462
.19 0.11 0.36
 2,735 75,403 9,362 21,268 2,621
 4,931 7,8141 9,902 25,468 2,616
 15,186 80,867 6,028 24,093 3,891
.70 0.76 0.26
 13,163 70,835 7,423 28,003 2,573
 3,633† 16,189 9,024* 12,249 2,616‡
 1,751† 13,019 9,911* 9,965 907‡
017 0.001 0.0001
repeated measures ANOVA for the 3 time points for each variable.
ach group with Bonferroni multiple comparisons test (3 comparisons).L/m-aoB, a
OxPL
4,438
8,159
4,236
0
7,229
3,229
5,867
0
2,736
5,734
2,556
0.
esentstherogenic potential of Lp(a).
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APPENDIX
For a supplemental figure, methods, and table,
please see the online version of this article.
